Phenotypes Associated with This Genotype

Genotype
MGI:5000457

• Allelic Composition: Cd19^tm1Tft/Cd19^tm1Tft
• Genetic Background: B6.Cg-Cd19^tm1Tft

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

increased CD8-positive, alpha-beta T cell number ( J:106487 )

• in MOG-treated mice

abnormal B cell physiology ( J:136210 )

• B cells stimulated with hyaluronan, heparan sulfate, and HMBG1 exhibit reduced cytokine over-production (IL6, IL10, IFN-gamma, TNF, and MIP-2) compared with similarly treated wild-type cells

decreased IgA level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgG1 level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgG2a level ( J:136210 )

• in bleomycin-treated mice

decreased IgG2b level ( J:136210 )

• in bleomycin-treated mice

decreased IgG3 level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgM level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interferon-gamma level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-10 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-4 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-6 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating tumor necrosis factor level ( J:136210 )

• in bleomycin-treated mice

increased interferon-gamma secretion ( J:106487 )

• in B cells stimulated with MOG and anti-CD40 antibodies

decreased interleukin-10 secretion ( J:106487 )

• in B cells stimulated with MOG and anti-CD40 antibodies

increased susceptibility to experimental autoimmune encephalomyelitis ( J:106487 )

• MOG-treated mice exhibit increased histological score, more severe inflammation, increased CD8+ T cells, wider spread demyelination, decreased IgM and IgG anti-MOG antibody production, and a Th1 bias with increased IFN-gamma production compared with similarly treated wild-type mice

• adoptive transfer of B cells increased susceptibility to experimental autoimmune encephalomyelitis in recipient wild-type mice

decreased anti-nuclear antigen antibody level ( J:136210 )

• untreated and bleomycin-treated mice exhibit reduced anti-topoisomerase I, anti-U1-RNP, anti-ssDNA, anti-histone, anti-dsDNA autoantibodies compared with wild-type mice

decreased anti-double stranded DNA antibody level ( J:136210 )

• in untreated and bleomycin-treated mice

nervous system

demyelination ( J:106487 )

• in MOG-treated mice

hematopoietic system

increased CD8-positive, alpha-beta T cell number ( J:106487 )

• in MOG-treated mice

abnormal B cell physiology ( J:136210 )

• B cells stimulated with hyaluronan, heparan sulfate, and HMBG1 exhibit reduced cytokine over-production (IL6, IL10, IFN-gamma, TNF, and MIP-2) compared with similarly treated wild-type cells

decreased IgA level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgG1 level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgG2a level ( J:136210 )

• in bleomycin-treated mice

decreased IgG2b level ( J:136210 )

• in bleomycin-treated mice

decreased IgG3 level ( J:136210 )

• in untreated and bleomycin-treated mice

decreased IgM level ( J:136210 )

• in bleomycin-treated mice

homeostasis/metabolism

decreased circulating interferon-gamma level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-10 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-4 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating interleukin-6 level ( J:136210 )

• in bleomycin-treated mice

decreased circulating tumor necrosis factor level ( J:136210 )

• in bleomycin-treated mice

decreased physiological sensitivity to xenobiotic ( J:136210 )

• bleomycin-treated mice exhibit decreased dermal infiltration (mast cells, macrophages, T and B cells), dermal thickening, skin and lung fibrosis, cytokine overproduction in the skin and serum (IL4, IL6, IL10, IFN-gamma, TNF, and MIP-2), hyaluronan overproduction, and autoantibody production compared with similarly treated wild-type mice

integument

thick dermal layer ( J:136210 )

• bleomycin-treated mice exhibit reduced dermal thickening compared with similarly treated wild-type mice

skin fibrosis ( J:136210 )

• bleomycin-treated mice exhibit reduced skin fibrosis compared with similarly treated wild-type mice